Drug profile · INN
pyridostigmine bromide
MESTINON
pyridostigmine bromide (MESTINON) is a acetylcholinesterase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — pyridostigmine bromide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 5
- Programs
- 0
- Data quality
- 0.89
Quick answer
pyridostigmine bromide (MESTINON) is a acetylcholinesterase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Acetylcholinesterase inhibitor
Primary target: Acetylcholinesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
-
US 12233166
Extended release compositions comprising pyridostigmine
granted -
US 11911515
Extended release compositions comprising pyridostigmine
granted -
US 11666536
Extended release compositions comprising pyridostigmine
granted -
US 11478425
Extended release compositions comprising pyridostigmine
granted -
US 11229606
Extended release compositions comprising pyridostigmine
granted
Frequently asked questions
What is pyridostigmine bromide?
pyridostigmine bromide (MESTINON) is a acetylcholinesterase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pyridostigmine bromide?
MESTINON is a marketed brand name for pyridostigmine bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pyridostigmine bromide?
pyridostigmine bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.